WO2023066133A1 - 抗间皮素纳米抗体及其用途 - Google Patents
抗间皮素纳米抗体及其用途 Download PDFInfo
- Publication number
- WO2023066133A1 WO2023066133A1 PCT/CN2022/125135 CN2022125135W WO2023066133A1 WO 2023066133 A1 WO2023066133 A1 WO 2023066133A1 CN 2022125135 W CN2022125135 W CN 2022125135W WO 2023066133 A1 WO2023066133 A1 WO 2023066133A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antigen
- nanobody
- binding fragment
- seq
- sequence
- Prior art date
Links
- 108010003723 Single-Domain Antibodies Proteins 0.000 title abstract description 47
- 230000027455 binding Effects 0.000 claims abstract description 150
- 238000009739 binding Methods 0.000 claims abstract description 142
- 239000000427 antigen Substances 0.000 claims abstract description 134
- 108091007433 antigens Proteins 0.000 claims abstract description 132
- 102000036639 antigens Human genes 0.000 claims abstract description 132
- 239000012634 fragment Substances 0.000 claims abstract description 103
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 40
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 38
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 38
- 101000576802 Homo sapiens Mesothelin Proteins 0.000 claims abstract 11
- 102100025096 Mesothelin Human genes 0.000 claims abstract 11
- 210000004027 cell Anatomy 0.000 claims description 93
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 69
- 229920001184 polypeptide Polymers 0.000 claims description 67
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 67
- 238000006467 substitution reaction Methods 0.000 claims description 59
- 241000282414 Homo sapiens Species 0.000 claims description 53
- 238000000034 method Methods 0.000 claims description 47
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 45
- 206010028980 Neoplasm Diseases 0.000 claims description 37
- 239000013598 vector Substances 0.000 claims description 36
- 238000007792 addition Methods 0.000 claims description 35
- 238000012217 deletion Methods 0.000 claims description 35
- 230000037430 deletion Effects 0.000 claims description 35
- 108090000623 proteins and genes Proteins 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 23
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 22
- 102000004169 proteins and genes Human genes 0.000 claims description 21
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 20
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims description 19
- 238000001514 detection method Methods 0.000 claims description 19
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 239000003153 chemical reaction reagent Substances 0.000 claims description 15
- 108060003951 Immunoglobulin Proteins 0.000 claims description 13
- 102000018358 immunoglobulin Human genes 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 11
- 229960002685 biotin Drugs 0.000 claims description 10
- 235000020958 biotin Nutrition 0.000 claims description 10
- 239000011616 biotin Substances 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 108090000790 Enzymes Proteins 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 8
- 230000008685 targeting Effects 0.000 claims description 8
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 7
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 7
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical class [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 claims description 7
- 239000007850 fluorescent dye Substances 0.000 claims description 7
- -1 hormonal drugs Substances 0.000 claims description 7
- 239000012642 immune effector Substances 0.000 claims description 7
- 238000003018 immunoassay Methods 0.000 claims description 7
- 229940121354 immunomodulator Drugs 0.000 claims description 7
- 229910052707 ruthenium Inorganic materials 0.000 claims description 7
- 238000002560 therapeutic procedure Methods 0.000 claims description 7
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 6
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical class C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 claims description 6
- 102000034287 fluorescent proteins Human genes 0.000 claims description 6
- 108091006047 fluorescent proteins Proteins 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 206010027406 Mesothelioma Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 230000000259 anti-tumor effect Effects 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000013604 expression vector Substances 0.000 claims description 5
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 241000282836 Camelus dromedarius Species 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 238000002965 ELISA Methods 0.000 claims description 3
- 229940034982 antineoplastic agent Drugs 0.000 claims description 3
- 230000004068 intracellular signaling Effects 0.000 claims description 3
- 230000035772 mutation Effects 0.000 claims description 3
- 125000006850 spacer group Chemical group 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 210000001124 body fluid Anatomy 0.000 claims description 2
- 238000004113 cell culture Methods 0.000 claims description 2
- 239000013599 cloning vector Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000002254 cytotoxic agent Substances 0.000 claims description 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- 210000004602 germ cell Anatomy 0.000 claims description 2
- 239000000367 immunologic factor Substances 0.000 claims description 2
- 238000010324 immunological assay Methods 0.000 claims description 2
- 210000000822 natural killer cell Anatomy 0.000 claims description 2
- 238000003127 radioimmunoassay Methods 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 238000001262 western blot Methods 0.000 claims description 2
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 abstract description 8
- 239000000203 mixture Substances 0.000 abstract description 4
- 102000003735 Mesothelin Human genes 0.000 description 53
- 108090000015 Mesothelin Proteins 0.000 description 53
- 235000001014 amino acid Nutrition 0.000 description 30
- 239000000243 solution Substances 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 16
- 229940024606 amino acid Drugs 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 239000002953 phosphate buffered saline Substances 0.000 description 12
- 230000006870 function Effects 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 125000000539 amino acid group Chemical group 0.000 description 10
- 239000011324 bead Substances 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 9
- 238000010494 dissociation reaction Methods 0.000 description 9
- 230000005593 dissociations Effects 0.000 description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 8
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 8
- 239000012636 effector Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 241000282693 Cercopithecidae Species 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 229950001537 amatuximab Drugs 0.000 description 6
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 6
- 239000008228 bacteriostatic water for injection Substances 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 239000008215 water for injection Substances 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 108010087819 Fc receptors Proteins 0.000 description 4
- 102000009109 Fc receptors Human genes 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 101100185026 Mus musculus Msln gene Proteins 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 241001416177 Vicugna pacos Species 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 4
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282842 Lama glama Species 0.000 description 3
- 241001631646 Papillomaviridae Species 0.000 description 3
- 108010004729 Phycoerythrin Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000008366 buffered solution Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000009509 drug development Methods 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 229940068977 polysorbate 20 Drugs 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 210000005253 yeast cell Anatomy 0.000 description 3
- OBYNJKLOYWCXEP-UHFFFAOYSA-N 2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]-4-isothiocyanatobenzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(N=C=S)=CC=C1C([O-])=O OBYNJKLOYWCXEP-UHFFFAOYSA-N 0.000 description 2
- 235000002198 Annona diversifolia Nutrition 0.000 description 2
- 108091008875 B cell receptors Proteins 0.000 description 2
- 230000003844 B-cell-activation Effects 0.000 description 2
- 241000251730 Chondrichthyes Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 2
- 210000004507 artificial chromosome Anatomy 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 229960004926 chlorobutanol Drugs 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 229960003742 phenol Drugs 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- JFJNVIPVOCESGZ-UHFFFAOYSA-N 2,3-dipyridin-2-ylpyridine Chemical compound N1=CC=CC=C1C1=CC=CN=C1C1=CC=CC=N1 JFJNVIPVOCESGZ-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 241000499489 Castor canadensis Species 0.000 description 1
- 102000014447 Complement C1q Human genes 0.000 description 1
- 108010078043 Complement C1q Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 101100421450 Drosophila melanogaster Shark gene Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241001524679 Escherichia virus M13 Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 235000011779 Menyanthes trifoliata Nutrition 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101150064776 Msln gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229950006588 anetumab ravtansine Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001511 capsicum annuum Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- SURLGNKAQXKNSP-DBLYXWCISA-N chlorin Chemical compound C\1=C/2\N/C(=C\C3=N/C(=C\C=4NC(/C=C\5/C=CC/1=N/5)=CC=4)/C=C3)/CC\2 SURLGNKAQXKNSP-DBLYXWCISA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000012893 effector ligand Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000005305 interferometry Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000005033 mesothelial cell Anatomy 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229940125645 monoclonal antibody drug Drugs 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000002818 protein evolution Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000009418 renovation Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 150000003303 ruthenium Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Definitions
- the present invention relates to Nanobodies or antigen-binding fragments thereof that specifically bind to MSLN, compositions containing said Nanobodies or antigen-binding fragments thereof, nucleic acids encoding said antibodies or antigen-binding fragments thereof and host cells comprising them, and related use. Furthermore, the invention relates to therapeutic and diagnostic uses of these antibodies or antigen-binding fragments thereof.
- MSLN Mesothelin
- MSLN Mesothelin
- MSLN is a 40kDa cell surface glycoprotein highly expressed in pancreatic cancer, ovarian cancer, mesothelioma and some other cancers. Because MSLN can also exist in the blood of a small number of patients in the secreted form of sMSLN, the determination of MSLN in blood may be useful for diagnosis and follow-up of the patient's condition.
- the MSLN gene encodes a 69-kDa precursor protein that is processed into a 40-kDa membrane-bound protein (called MSLN) and a 31-kDa shedding fragment called megakaryocyte-potentiating factor (MPF) ), the fragment is released from the cell.
- MSLN 40-kDa membrane-bound protein
- MPF megakaryocyte-potentiating factor
- MSLN is not a cancer-specific antigen, it can be expressed in mesothelial cells of normal pleura, pericardium and peritoneum, but it is highly expressed in a variety of cancer cells.
- the limited distribution of MSLN in normal tissues makes it a potential target for tumor-specific therapy.
- Anetumab ravtansine an antibody-conjugated drug developed by companies such as Bayer, ImmunoGen, and Morphosys
- Amatuximab a monoclonal antibody drug targeting MSLN developed by Morphotek
- the trial has also advanced to clinical phase II for the clinical treatment of solid tumors; in addition, the Military Medical College of the Chinese People's Liberation Army and TCR2 have also developed CAR-T therapy targeting MSLN, which are currently in the clinical trial stage.
- Existing clinical trials mostly show that the safety of mesothelin-targeted therapy is acceptable, but the therapeutic effect is mediocre.
- Single domain antibody also known as nanobody (nanobody) or heavy chain antibody (hcAb) is an antibody isolated from the serum of camelids and sharks, and its volume is about 1/10 of traditional antibodies.
- single-domain antibodies are only composed of heavy chains, and their antigen-binding region is only a single domain connected to the Fc region through a hinge region, and this antigen-binding region still has the ability to bind antigen after it is separated from the antibody. Function.
- Single-domain antibodies have the characteristics of small molecular weight and good stability. Compared with traditional common normal antibodies in drug development and diagnostic reagent development, they have good tissue infiltration, flexible administration methods, high degree of humanization, and easy protein recombination. renovation and many other advantages.
- the inventors of the present application screened and obtained nanobodies against MSLN, which have high binding activity to MSLN and have cross-reactivity with human, monkey and/or mouse MSLN.
- the nanobody also has the characteristics of small molecular weight and good stability. Compared with traditional common normal antibodies in drug development and diagnostic reagent development, it has good tissue infiltration, flexible administration methods, and a high degree of humanization. , easy recombinant protein transformation and many other advantages.
- the present application also provides a composition containing the Nanobody or an antigen-binding fragment thereof, a nucleic acid encoding the Nanobody or an antigen-binding fragment thereof, a host cell comprising the same, and related uses.
- the present application provides Nanobodies or antigen-binding fragments thereof capable of specifically binding to MSLN.
- the Nanobodies described herein generally consist of four framework regions (FRs) and three complementarity determining regions (CDRs), termed FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4, the antigen-binding fragment comprising the At least a portion of a Nanobody sufficient to confer on the fragment the ability to specifically bind MSLN.
- the Nanobodies according to the invention may be truncated at the N-terminus or C-terminus so that they only comprise part of FR1 and/or FR4, or lack one or both of those framework regions, as long as they are substantially It is sufficient to maintain antigen binding and specificity.
- the Nanobody or antigen-binding fragment thereof comprises:
- VHH variable region
- the variant has one or several amino acid substitutions, deletions or additions (eg, 1, 2 or 3 amino acid substitutions, deletions or additions) compared to the sequence from which it is derived.
- the substitutions are conservative substitutions.
- the CDRs are defined according to the IMGT, Kabat or Chothia numbering system.
- the Nanobody or antigen-binding fragment thereof comprises:
- the sequence is the CDR1 of SEQ ID NO: 1 or a variant thereof, the sequence is the CDR2 of SEQ ID NO: 2 or a variant thereof, and the sequence is the CDR3 of SEQ ID NO: 3 or a variant thereof;
- the variant has one or several amino acid substitutions, deletions or additions (eg, 1, 2 or 3 amino acid substitutions, deletions or additions) compared to the sequence from which it is derived.
- the substitutions are conservative substitutions.
- the Nanobody or antigen-binding fragment thereof comprises: CDR1 having the sequence of SEQ ID NO:1, CDR2 having the sequence of SEQ ID NO:2, and CDR3 having the sequence of SEQ ID NO:3.
- the CDRs are defined by the IMGT numbering system.
- the Nanobody or antigen-binding fragment thereof comprises an amino acid sequence selected from:
- the substitutions are conservative substitutions.
- the Nanobody or antigen-binding fragment thereof is humanized.
- the Nanobody or antigen-binding fragment thereof further comprises a heavy chain framework region of a human immunoglobulin (e.g., a heavy chain framework region comprised in the amino acid sequence encoded by a human heavy chain germline antibody gene ), said heavy chain framework region optionally comprising one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) from Back mutation of human residues to camel residues.
- a human immunoglobulin e.g., a heavy chain framework region comprised in the amino acid sequence encoded by a human heavy chain germline antibody gene
- said heavy chain framework region optionally comprising one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10) from Back mutation of human residues to camel residues.
- the Nanobody or antigen-binding fragment thereof comprises:
- the Nanobody or antigen-binding fragment thereof comprises an amino acid sequence selected from:
- (iii) have at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95% of the sequence shown in any one of SEQ ID NOs: 6-9 , at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity.
- the substitutions are conservative substitutions.
- the present application also provides a polypeptide construct specifically binding to MSLN, which comprises a Nanobody or an antigen-binding fragment thereof as described above, and an immunoglobulin Fc domain.
- the Fc domain is also referred to as Fc region, and refers to a part of the heavy chain constant region including CH2 and CH3.
- the Fc domain comprises a hinge, CH2 and CH3.
- the hinge mediates dimerization between two Fc-containing polypeptides.
- the Fc domain can be of any antibody heavy chain constant region isotype.
- the Fc domain is IgGl, IgG2, IgG3 or IgG4.
- the Fc domain comprised by the polypeptide construct of the present invention is a native Fc region comprising an amino acid sequence identical to that of an Fc region found in nature.
- the Fc domain can be a native sequence human IgGl Fc region, a native sequence human IgG2 Fc region, a native sequence human IgG3 Fc region, or a native sequence human IgG4 Fc region.
- a native Fc region may have effector functions. Exemplary "effector functions" include binding to Fc receptors; Clq binding and complement-dependent cytotoxicity (CDC); antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; downregulation of B cell receptors); and B cell activation, among others.
- Effector function can be altered by substituting at least one amino acid residue in the native Fc region with a different residue or by chemical modification, e.g., altering the affinity of the antibody for an effector ligand such as FcR or complement C1q (e.g. decrease or increase).
- the Fc domain comprised by the polypeptide construct of the present invention may also be a variant Fc region, which may comprise one or more (for example 1-10, for example 1- 5) Amino acid mutation or chemical modification to change one or more of the following properties of the antibody of the invention: Fc receptor binding, antibody glycosylation, number of cysteine residues, effector cell function or complement function, etc. .
- the Fc domain contained in the polypeptide construct of the present invention has ADCC activity. In some embodiments, the Fc domain contained in the polypeptide construct of the present invention does not have ADCC activity.
- said immunoglobulin Fc domain is linked to the N-terminus and/or C-terminus (eg, C-terminus) of said Nanobody or antigen-binding fragment thereof, optionally via a peptide linker.
- the immunoglobulin Fc domain is an IgG Fc domain (eg, an IgGl Fc domain).
- the immunoglobulin Fc domain comprises the sequence shown in SEQ ID NO: 5, or has at least 80%, at least 85%, at least 90%, at least 91%, at least 92% compared thereto , at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity, or have one or several amino acid substitutions compared thereto , a sequence deleted or added (eg, 1, 2, 3, 4 or 5 amino acid substitutions, deletions or additions).
- the Nanobody or polypeptide construct of the present invention can be prepared by various methods known in the art, for example, by genetic engineering and recombination techniques.
- a DNA molecule encoding a Nanobody or polypeptide construct of the invention is obtained by chemical synthesis or PCR amplification.
- the resulting DNA molecule is inserted into an expression vector and then transfected into a host cell. Then, the transfected host cells are cultured under specific conditions, and express the antibody or polypeptide construct of the present invention.
- the antigen-binding fragments of the present invention can be obtained by hydrolyzing the complete Nanobody molecule (see Morimoto et al., J. Biochem. Biophys. Methods 24:107-117 (1992) and Brennan et al., Science 229:81 (1985) ). In addition, these antigen-binding fragments can also be directly produced by recombinant host cells (reviewed in Hudson, Curr. Opin. Immunol. 11:548-557 (1999); Little et al., Immunol. Today, 21:364-370 (2000 )). Other techniques for preparing these antigen-binding fragments are well known to those of ordinary skill in the art.
- the present application also provides an isolated nucleic acid molecule encoding a Nanobody or antigen-binding fragment thereof as described above or a polypeptide construct as described above.
- the present application also provides a vector comprising the nucleic acid molecule as described above.
- the vector is a cloning vector or an expression vector.
- the present application also provides a host cell comprising the nucleic acid molecule or vector as described above.
- host cells include, but are not limited to, prokaryotic cells such as bacterial cells (such as E. coli cells), and eukaryotic cells such as fungal cells (such as yeast cells), insect cells, plant cells, and animal cells (such as mammalian cells, such as small mouse cells, human cells, etc.).
- the present application also provides a method for preparing a Nanobody or an antigen-binding fragment thereof as described above or a polypeptide construct as described above, which comprises, under conditions that allow protein expression, culturing the host as described above cells, and recovering said Nanobody or antigen-binding fragment thereof or said polypeptide construct from cultured host cell culture.
- the present application also provides a bispecific or multispecific antibody comprising a Nanobody or an antigen-binding fragment thereof as described above or a polypeptide construct as described above.
- the present application also provides the use of the Nanobodies or their antigen-binding fragments or polypeptide constructs of the present invention, or nucleic acid molecules, vectors or host cells encoding them, for the preparation of bispecific or multispecific antibodies.
- the bispecific or multispecific antibody specifically binds MSLN and additionally specifically binds one or more other targets.
- the bispecific or multispecific antibody further comprises at least one second antibody having a second binding specificity for a second target.
- the present application also provides a conjugate comprising a Nanobody or an antigen-binding fragment thereof as described above or a polypeptide construct as described above, and a Nanobody or an antigen-binding fragment thereof or a polypeptide construct as described above. body-linked therapeutics.
- the present application also provides the use of Nanobodies or antigen-binding fragments thereof or polypeptide constructs of the invention, or nucleic acid molecules, vectors or host cells encoding them, for the preparation of conjugates.
- the therapeutic agent is selected from antineoplastic agents, such as cytotoxic agents, hormonal agents, biological response modifiers, additional antibodies or antigen-binding fragments thereof.
- the present application also provides a chimeric antigen receptor comprising an antigen-binding domain, a spacer domain, a transmembrane domain, and an intracellular signaling domain (such as a primary signaling domain and/or costimulatory domain). signaling domain), wherein said antigen binding domain comprises a Nanobody or an antigen binding fragment thereof as described above.
- the present application also provides Nanobodies or antigen-binding fragments thereof or polypeptide constructs of the present invention, or nucleic acid molecules encoding them, vectors or host cells for use in preparing chimeric antigen receptors or expressing said chimeric antigen receptors for immunization The purpose of the cells.
- the antigen binding domain confers on the chimeric antigen receptor the ability to recognize MSLN;
- the spacer domain allows the protein to be flexible and allows movement of one or both domains relative to each other;
- the transmembrane domain can be thermodynamically stable in the cell membrane (especially the eukaryotic cell membrane);
- the intracellular signaling domain participates in transducing effective antigen-receptor binding signals into the immune effector cells, and activates the immune effector that expresses CAR At least one normal effector function of the cell, or enhanced secretion of at least one cytokine by the CAR-expressing immune effector cell.
- the chimeric antigen receptor is expressed by immune effector cells (eg, T cells).
- immune effector cells eg, T cells
- the present application also provides an isolated nucleic acid molecule encoding a chimeric antigen receptor as described above.
- the present application also provides a vector comprising the isolated nucleic acid molecule as described above.
- the isolated nucleic acid molecules are used to generate chimeric antigen receptor T cells.
- the present application also provides a host cell comprising the isolated nucleic acid molecule or vector as described above.
- the host cells are immune effector cells (eg, T cells or NK cells).
- the host cell is a chimeric antigen receptor T cell (CAR-T).
- CAR-T chimeric antigen receptor T cell
- the present application also provides a pharmaceutical composition, which comprises the Nanobody or antigen-binding fragment thereof of the first aspect, the polypeptide construct of the second aspect, and the bispecific or multispecific antibody of the seventh aspect as described above.
- the pharmaceutical composition further comprises a pharmaceutically acceptable carrier and/or excipient.
- the pharmaceutically acceptable carrier and/or excipient comprises a sterile injectable liquid (eg, aqueous or non-aqueous suspension or solution).
- a sterile injectable liquid eg, aqueous or non-aqueous suspension or solution.
- sterile injectable liquids are selected from the group consisting of water for injection (WFI), bacteriostatic water for injection (BWFI), sodium chloride solution (eg 0.9% (w/v) NaCl), dextrose solutions (eg, 5% glucose), solutions containing surfactants (eg, 0.01% polysorbate 20), pH buffered solutions (eg, phosphate buffered saline), Ringer's solutions, and any combination thereof.
- WFI water for injection
- BWFI bacteriostatic water for injection
- sodium chloride solution eg 0.9% (w/v) NaCl
- dextrose solutions eg, 5% glucose
- surfactants eg, 0.01% polysorbate 20
- the pharmaceutical composition comprises the Nanobody or antigen-binding fragment thereof of the first aspect, the polypeptide construct of the second aspect, the isolated nucleic acid molecule of the third aspect, the A vector or host cell of the fifth aspect.
- the pharmaceutical composition comprises the bispecific or multispecific antibody of the seventh aspect as described above.
- the pharmaceutical composition comprises the conjugate of the eighth aspect as described above.
- the pharmaceutical composition comprises the chimeric antigen receptor of the ninth aspect, the isolated nucleic acid molecule of the tenth aspect, the carrier of the eleventh aspect, or the host of the twelfth aspect as described above cell.
- the present application also provides the Nanobody or antigen-binding fragment thereof in the first aspect, the polypeptide construct in the second aspect, the bispecific or multispecific antibody in the seventh aspect, the eighth aspect
- the conjugate of the aspect, the chimeric antigen receptor of the ninth aspect, the isolated nucleic acid molecule of the third aspect or the tenth aspect, the vector of the fourth aspect or the eleventh aspect, the host of the fifth aspect or the twelfth aspect Use of the cell, or the pharmaceutical composition of the thirteenth aspect for the preparation of a medicament for preventing and/or treating tumors in a subject.
- the tumor is a MSLN positive tumor.
- the tumor is selected from solid tumors such as gastric cancer, lung cancer, ovarian cancer, esophageal cancer, pancreatic cancer, cervical cancer, mesothelioma or breast cancer.
- solid tumors such as gastric cancer, lung cancer, ovarian cancer, esophageal cancer, pancreatic cancer, cervical cancer, mesothelioma or breast cancer.
- Such tumors are known in the art to highly express MSLN (see e.g. Aurore et al., cancer discovery, 2016).
- the subject is a mammal, such as a human.
- the Nanobody or antigen-binding fragment thereof, polypeptide construct, isolated nucleic acid molecule, vector, host cell, bispecific or multispecific antibody, conjugate, chimeric antigen receptor, Or the pharmaceutical composition is used alone, or used in combination with another pharmaceutically active agent (such as an antineoplastic agent).
- another pharmaceutically active agent such as an antineoplastic agent.
- the present application also provides a method for preventing and/or treating tumors in a subject, which includes: administering an effective amount of the above-mentioned first aspect to a subject in need thereof Nanobody or antigen-binding fragment thereof, polypeptide construct of the second aspect, bispecific or multispecific antibody of the seventh aspect, conjugate of the eighth aspect, chimeric antigen receptor of the ninth aspect, third aspect Or the isolated nucleic acid molecule of the tenth aspect, the vector of the fourth or eleventh aspect, the host cell of the fifth or twelfth aspect, or the pharmaceutical composition of the thirteenth aspect.
- the tumor is a MSLN positive tumor.
- the tumor is selected from solid tumors such as gastric cancer, lung cancer, ovarian cancer, esophageal cancer, pancreatic cancer, cervical cancer, mesothelioma or breast cancer.
- the subject is a mammal, such as a human.
- Nanobodies or antigen-binding fragments thereof, polypeptide constructs, bispecific or multispecific antibodies, or pharmaceutical compositions of the present application can be formulated into any dosage form known in the medical field, for example, tablets, pills, suspensions, Emulsions, solutions, gels, capsules, powders, granules, elixirs, lozenges, suppositories, injections (including injections, sterile powders for injections and concentrated solutions for injections), inhalants, sprays, etc.
- the preferred dosage form depends on the intended mode of administration and therapeutic use.
- Nanobodies or antigen-binding fragments thereof, polypeptide constructs, bispecific or multispecific antibodies, or pharmaceutical compositions of the invention should be sterile and stable under the conditions of manufacture and storage.
- a preferred dosage form is injection.
- Such injections can be sterile injectable solutions.
- sterile injectable solutions can be prepared by incorporating the necessary doses of a Nanobody or antigen-binding fragment thereof, polypeptide construct, bispecific or multispecific antibody, or drug of the invention in an appropriate solvent composition, and optionally, simultaneously incorporate other desired ingredients (including but not limited to, pH adjusters, surfactants, adjuvants, ionic strength enhancers, isotonic agents, preservatives, diluents, or any combination), followed by filter sterilization.
- sterile injectable solutions can be prepared as sterile lyophilized powder (eg, by vacuum drying or freeze-drying) for ease of storage and use.
- Such sterile lyophilized powders can be dispersed in suitable carriers before use, such as water for injection (WFI), bacteriostatic water for injection (BWFI), sodium chloride solution (such as 0.9% (w/v) NaCl), Dextrose solution (eg 5% glucose), surfactant containing solution (eg 0.01% polysorbate 20), pH buffered solution (eg phosphate buffered saline), Ringer's solution and any combination thereof.
- WFI water for injection
- BWFI bacteriostatic water for injection
- sodium chloride solution such as 0.9% (w/v) NaCl
- Dextrose solution eg 5% glucose
- surfactant containing solution eg 0.01% polysorbate 20
- pH buffered solution eg phosphate buffered saline
- Ringer's solution any combination thereof.
- Nanobodies or antigen-binding fragments thereof, polypeptide constructs, bispecific or multispecific antibodies, or pharmaceutical compositions of the present application may be administered by any suitable method known in the art, including but not limited to, oral, buccal , sublingual, ocular, topical, parenteral, rectal, intrathecal, intracytoplasmic reticulum, inguinal, intravesical, topical (eg, powder, ointment, or drops), or nasal routes.
- the preferred route/mode of administration is parenteral (eg, intravenous or bolus injection, subcutaneous injection, intraperitoneal injection, intramuscular injection).
- a Nanobody or antigen-binding fragment thereof, polypeptide construct, bispecific or multispecific antibody, or pharmaceutical composition of the invention is administered by intravenous injection or bolus injection.
- the present application also provides a conjugate comprising a Nanobody or an antigen-binding fragment thereof as described above or a polypeptide construct as described above, and a nanobody or an antigen-binding fragment thereof or a polypeptide as described above.
- Construct-linked detectable labels such as enzymes (such as horseradish peroxidase or alkaline phosphatase), chemiluminescent reagents (such as acridinium esters, luminol and its derivatives, or ruthenium derivatives) , fluorescent dyes (such as fluorescein or fluorescent protein), radionuclides or biotin.
- the present application also provides a kit comprising the Nanobody or antigen-binding fragment thereof as described above or the polypeptide construct as described above or the conjugate of the sixteenth aspect as described above.
- the kit comprises the conjugate of the sixteenth aspect as described above.
- the kit comprises a Nanobody, or an antigen-binding fragment thereof, or a polypeptide construct as described above, and a protein that specifically recognizes said Nanobody, or an antigen-binding fragment thereof, or a polypeptide construct.
- Second antibody also includes a detectable label, such as an enzyme (such as horseradish peroxidase or alkaline phosphatase), a chemiluminescence reagent (such as acridinium esters, luminamine fluorescein and its derivatives, or ruthenium derivatives), fluorescent dyes (such as fluorescein or fluorescent protein), radionuclides or biotin.
- an enzyme such as horseradish peroxidase or alkaline phosphatase
- chemiluminescence reagent such as acridinium esters, luminamine fluorescein and its derivatives, or ruthenium derivatives
- fluorescent dyes such as fluorescein or fluorescent protein
- the present application also provides a method for detecting the presence or level of MSLN in a sample, comprising using a Nanobody as described above or an antigen-binding fragment thereof or a polypeptide construct as described above or as described above The conjugate of the sixteenth aspect.
- the methods are used for therapeutic purposes, diagnostic purposes, or non-therapeutic non-diagnostic purposes.
- the method is an immunological assay, such as a western blot, an enzyme immunoassay (eg, ELISA), a chemiluminescent immunoassay, a fluorescent immunoassay, or a radioimmunoassay.
- the method comprises using the conjugate of the sixteenth aspect as described above.
- the method comprises the use of a Nanobody or antigen-binding fragment thereof as described above or a polypeptide construct as described above, and the method further comprises the use of a nanobody carrying a detectable label (e.g. an enzyme (e.g. paprika) root peroxidase or alkaline phosphatase), chemiluminescent reagents (such as acridinium esters, luminol and its derivatives, or ruthenium derivatives), fluorescent dyes (such as fluorescein or fluorescent protein), radioactive nuclei or biotin) to detect the Nanobody or antigen-binding fragment or polypeptide construct thereof.
- a detectable label e.g. an enzyme (e.g. paprika) root peroxidase or alkaline phosphatase)
- chemiluminescent reagents such as acridinium esters, luminol and its derivatives, or ruthenium derivatives
- fluorescent dyes such as fluorescein or
- the method comprises: (1) combining the sample with a Nanobody of the invention or an antigen-binding fragment thereof, a polypeptide construct of the invention, or a conjugate of the sixteenth aspect of the invention contacting; (2) detecting the formation of antigen-antibody immune complexes or detecting the amount of said immune complexes.
- the formation of such immune complexes indicates the presence of MSLN or cells expressing MSLN.
- the method is used to detect whether a tumor can be treated by an anti-tumor therapy targeting MSLN.
- the present application also provides the above-mentioned Nanobody or its antigen-binding fragment or the above-mentioned polypeptide construct or the above-mentioned conjugate of the sixteenth aspect in preparation for detecting MSLN in The presence or level thereof in a sample or use in a detection reagent for detecting whether a tumor can be treated by an anti-tumor therapy targeting MSLN.
- the detection reagent detects the presence or level of MSLN in the sample by the method of the eighteenth aspect as described above and optionally detects whether the tumor can be cured by anti-tumor therapy targeting MSLN treat.
- the sample is a sample of cells (eg, a sample comprising tumor cells) or a sample of bodily fluid (eg, blood) from a subject (eg, a mammal, eg, a human).
- a sample of cells eg, a sample comprising tumor cells
- a sample of bodily fluid eg, blood
- the term “camelid antibody” refers to an immunized or antigen-invaded camelid (Camelidae) animal (including camel (Camel), alpaca (Alpaca) and llama (L.glama) ) produced antibodies against the antigen.
- camelid camel
- alpaca Alphaaca
- llama L.glama
- HCAb heavy chain antibody
- Nanobody has the meaning commonly understood by those skilled in the art, which refers to an antibody consisting of a single monomer variable antibody domain (for example, a single heavy chain variable region) Fragments, typically derived from the variable region of a heavy chain antibody such as a camelid or shark antibody.
- a Nanobody consists of 4 framework regions and 3 complementarity determining regions, with a structure of FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. Nanobodies may be truncated at the N- or C-terminus so that they comprise only part of FR1 and/or FR4, or lack one or both of those framework regions, so long as they substantially retain antigen binding and specificity. Nanobodies are also known as single-domain antibodies (sdAbs), and the two are used interchangeably.
- sdAbs single-domain antibodies
- the term "antigen-binding fragment" of a Nanobody refers to a polypeptide comprising a fragment of a Nanobody that retains the ability to specifically bind to the same antigen to which the Nanobody binds, and/or competes with the Nanobody for antigen binding. It is also called "antigen-binding portion”. See generally, Fundamental Immunology, Ch.7 (Paul, W., ed., 2nd ed., Raven Press, N.Y. (1989), which is incorporated herein by reference in its entirety for all purposes. or by enzymatic or chemical cleavage of the Nanobodies of the invention to generate antigen-binding fragments of the antibodies of the invention.
- the "antigen-binding fragments" of the Nanobodies may be at the N-terminal or C-terminus compared to full-length Nanobodies. Truncated at the terminus so that it comprises only part of FR1 and/or FR4, or lacks one or both of those framework regions, so long as it substantially retains antigen binding and specificity.
- Antigen-binding fragments of a Nanobody can be obtained from a given Nanobody (such as a Nanobody provided by the invention) using conventional techniques known to those skilled in the art (for example, recombinant DNA techniques or enzymatic or chemical fragmentation methods), and can be obtained as Antigen-binding fragments of Nanobodies are screened for specificity in the same way as for whole Nanobodies.
- Nanobody includes not only whole Nanobodies but also antigen-binding fragments of Nanobodies.
- CDR complementarity determining region
- CDR1 complementarity determining region
- CDR2 complementarity determining region
- CDR3 complementarity determining region
- the precise boundaries of these CDRs can be defined according to various numbering systems known in the art, such as the Kabat numbering system (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991), the Chothia numbering system (Chothia & Lesk (1987) J. Mol. Biol. 196:901-917; Chothia et al.
- framework region or "FR” residues refers to those amino acid residues in an antibody variable region other than the CDR residues as defined above.
- the term "Fc domain” or "Fc region” means a part of the heavy chain constant region comprising CH2 and CH3.
- the Fc fragment of an antibody has a variety of different functions, but is not involved in antigen binding.
- "Effector functions" mediated by the Fc region include Fc receptor binding; Clq binding and complement-dependent cytotoxicity (CDC); antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; Downregulation of body (eg, B cell receptor); and B cell activation, etc.
- the Fc region comprises a hinge, CH2 and CH3. When the Fc region contains a hinge, the hinge mediates dimerization between two Fc-containing polypeptides.
- the Fc region can be of any antibody heavy chain constant region isotype, eg IgGl, IgG2, IgG3 or IgG4.
- the Fc domain can include both a native Fc region and a variant Fc region.
- a native Fc region comprises an amino acid sequence identical to that of an Fc region found in nature, for example, a native sequence human Fc region includes a native sequence human IgG1 Fc region (non-A and A allotypes); a native sequence human IgG2 Fc region; a native sequence human Fc region; an IgG3 Fc region; and a native sequence human IgG4 Fc region, and naturally occurring variants thereof.
- a variant Fc region comprises an amino acid sequence that differs from that of a native sequence Fc region by at least one amino acid modification.
- a variant Fc region may possess altered effector functions (e.g., Fc receptor binding, antibody glycosylation, number of cysteine residues, effector cell function, or complement function) compared to a native Fc region .
- the term "humanized antibody” refers to a genetically engineered non-human antibody whose amino acid sequence has been modified to increase sequence homology with a human antibody.
- all or part of the CDR region of a humanized antibody is derived from a non-human antibody (donor antibody), and all or part of the non-CDR region (for example, variable region FR and/or constant region) is derived from a human Immunoglobulin (receptor antibody).
- the CDR regions of a humanized antibody are derived from a non-human antibody (donor antibody), and all or part of the non-CDR regions (e.g., variable FR and/or constant regions) are derived from human Immunoglobulin (receptor antibody).
- Humanized antibodies generally retain the desired properties of the donor antibody, including, but not limited to, antigen specificity, affinity, reactivity, and the like.
- the donor antibody may be a camelid antibody with desired properties (eg, antigen specificity, affinity, reactivity, etc.).
- the CDR regions of the immunized animal can be inserted into human framework sequences using methods known in the art.
- a humanized antibody may refer to a humanized VHH, i.e. a VHH in which one or more framework regions have been substantially replaced by human framework regions. In some instances, certain framework regions (FRs) of the human immunoglobulin are replaced by corresponding non-human residues.
- a humanized VHH may contain residues that were not found in either the original VHH or the human framework sequence, but were included to further refine and optimize the properties of the VHH or VHH-containing polypeptide.
- the term "identity" is used to refer to the match of sequences between two polypeptides or between two nucleic acids.
- the sequences are aligned for optimal comparison purposes (for example, gaps may be introduced in a first amino acid sequence or nucleic acid sequence to best align with a second amino acid or nucleic acid sequence).
- Jiabi pair The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are identical at that position.
- the determination of percent identity between two sequences can also be accomplished using a mathematical algorithm.
- a non-limiting example of a mathematical algorithm for the comparison of two sequences is the algorithm of Karlin and Altschul, 1990, Proc. Modified from .Acad.Sci.U.S.A. 90:5873-5877. Such an algorithm was incorporated into the NBLAST and XBLAST programs of Altschul et al., 1990, J. Mol. Biol. 215:403.
- the term "specific binding” refers to a non-random binding reaction between two molecules, such as the reaction between an antibody and its antigen.
- the strength or affinity of a specific binding interaction can be expressed in terms of the equilibrium dissociation constant ( KD ) for that interaction.
- KD refers to the dissociation equilibrium constant of a specific antibody-antigen interaction, which is used to describe the binding affinity between an antibody and an antigen. The smaller the equilibrium dissociation constant, the tighter the antibody-antigen binding, and the higher the affinity between the antibody and the antigen.
- the specific binding properties between two molecules can be determined using methods well known in the art.
- One method involves measuring the rate of antigen binding site/antigen complex formation and dissociation.
- Both the "association rate constant” (ka or kon) and the “dissociation rate constant” (kdis or koff) can be calculated from the concentration and actual rates of association and dissociation (see Malmqvist M, Nature, 1993, 361 :186-187).
- the ratio kdis/kon is equal to the dissociation constant KD (see Davies et al., Annual Rev Biochem, 1990; 59:439-473).
- KD , kon and kdis values can be measured by any effective method.
- dissociation constants can be measured in Biacore using surface plasmon resonance (SPR).
- bioluminescent interferometry or Kinexa can be used to measure dissociation constants.
- a detectable label according to the invention can be any substance detectable by fluorescent, spectroscopic, photochemical, biochemical, immunological, electrical, optical or chemical means.
- labels are well known in the art, examples of which include, but are not limited to, enzymes (e.g., horseradish peroxidase, alkaline phosphatase, ⁇ -galactosidase, urease, glucose oxidase, etc.), radionuclide Chlorin (for example, 3 H, 125 I, 35 S, 14 C or 32 P), fluorescent dyes (for example, fluorescein isothiocyanate (FITC), fluorescein, tetramethylrhodamine isothiocyanate (TRITC) , phycoerythrin (PE), Texas Red, rhodamine, quantum dots or cyanine dye derivatives (such as Cy7, Alexa 750)), luminescent substances (such as chemiluminescent substances, such as acridine este
- vector refers to a nucleic acid delivery vehicle into which a polynucleotide can be inserted.
- the vector is called an expression vector.
- a vector can be introduced into a host cell by transformation, transduction or transfection, so that the genetic material elements it carries can be expressed in the host cell.
- Vectors are well known to those skilled in the art, including but not limited to: plasmids; phagemids; cosmids; artificial chromosomes, such as yeast artificial chromosomes (YAC), bacterial artificial chromosomes (BAC) or P1-derived artificial chromosomes (PAC) ; Phage such as lambda phage or M13 phage and animal viruses.
- artificial chromosomes such as yeast artificial chromosomes (YAC), bacterial artificial chromosomes (BAC) or P1-derived artificial chromosomes (PAC)
- Phage such as lambda phage or M13 phage and animal viruses.
- Animal viruses that can be used as vectors include, but are not limited to, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpesviruses (such as herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, papillomaviruses, papillomaviruses, Polyoma vacuolar virus (eg SV40).
- retroviruses including lentiviruses
- adenoviruses such as herpes simplex virus
- poxviruses such as herpes simplex virus
- baculoviruses such as herpes simplex virus
- baculoviruses such as herpes simplex virus
- papillomaviruses papillomaviruses
- papillomaviruses papillomaviruses
- Polyoma vacuolar virus eg
- the term "host cell” refers to cells that can be used to introduce vectors, including, but not limited to, prokaryotic cells such as Escherichia coli or Bacillus subtilis, fungal cells such as yeast cells or Aspergillus, Insect cells such as S2 Drosophila cells or Sf9, or animal cells such as fibroblasts, CHO cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK 293 cells or human cells.
- prokaryotic cells such as Escherichia coli or Bacillus subtilis
- fungal cells such as yeast cells or Aspergillus
- Insect cells such as S2 Drosophila cells or Sf9
- animal cells such as fibroblasts, CHO cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK 293 cells or human cells.
- conservative substitution means an amino acid substitution that does not adversely affect or alter the expected properties of the protein/polypeptide comprising the amino acid sequence.
- conservative substitutions can be introduced by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis.
- Conservative amino acid substitutions include substitutions for amino acid residues with amino acid residues that have similar side chains, e.g., are physically or functionally similar (e.g., have similar size, shape, charge, chemical properties, including Substitution of residues with the ability to form covalent or hydrogen bonds, etc.). Families of amino acid residues having similar side chains have been defined in the art.
- These families include those with basic side chains (e.g., lysine, arginine, and histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine) , asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), non-polar side chains (such as alanine, valine, leucine, isoleucine amino acid, proline, phenylalanine, methionine), beta branched side chains (e.g. threonine, valine, isoleucine) and aromatic side chains (e.g.
- basic side chains e.g., lysine, arginine, and histidine
- acidic side chains e.g., aspartic acid, glutamic acid
- uncharged polar side chains e.g., glycine
- non-polar side chains such as
- the term "pharmaceutically acceptable carrier and/or excipient” refers to a carrier and/or excipient compatible with the subject and the active ingredient pharmacologically and/or physiologically, These are well known in the art (see e.g. Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995), and include, but are not limited to: pH adjusters, surfactants, adjuvants, ionic strength enhancers agents, diluents, agents to maintain osmotic pressure, agents to delay absorption, preservatives.
- pH adjusting agents include, but are not limited to, phosphate buffers.
- Surfactants include but are not limited to cationic, anionic or nonionic surfactants such as Tween-80.
- Ionic strength enhancers include, but are not limited to, sodium chloride.
- Preservatives include, but are not limited to, various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, and the like.
- Agents to maintain osmotic pressure include, but are not limited to, sugars, NaCl, and the like.
- Agents that delay absorption include, but are not limited to, monostearates and gelatin.
- Diluents include, but are not limited to, water, aqueous buffers (eg, buffered saline), alcohols and polyols (eg, glycerol), and the like.
- Preservatives include, but are not limited to, various antibacterial and antifungal agents, such as thimerosal, 2-phenoxyethanol, parabens, chlorobutanol, phenol, sorbic acid, and the like.
- Stabilizer has the meaning generally understood by those skilled in the art, and it can stabilize the desired activity of the active ingredient in the medicine, including but not limited to sodium glutamate, gelatin, SPGA, sugars (such as sorbitol, mannitol, starch, sucrose , lactose, dextran, or glucose), amino acids (such as glutamic acid, glycine), proteins (such as dry whey, albumin or casein) or their degradation products (such as lactalbumin hydrolyzate), etc.
- the pharmaceutically acceptable carrier or excipient comprises a sterile injectable liquid (eg, aqueous or non-aqueous suspension or solution).
- such sterile injectable liquids are selected from the group consisting of water for injection (WFI), bacteriostatic water for injection (BWFI), sodium chloride solution (eg 0.9% (w/v) NaCl), dextrose solutions (eg, 5% dextrose), solutions containing surfactants (eg, 0.01% polysorbate 20), pH buffered solutions (eg, phosphate buffered saline), Ringer's solutions, and any combination thereof.
- WFI water for injection
- BWFI bacteriostatic water for injection
- sodium chloride solution eg 0.9% (w/v) NaCl
- dextrose solutions eg, 5% dextrose
- solutions containing surfactants eg, 0.01% polysorbate 20
- pH buffered solutions eg, phosphate buffered saline
- Ringer's solutions e.g, Ringer's solutions, and any combination thereof.
- prevention refers to methods performed to prevent or delay the occurrence of a disease or disorder or symptom in a subject.
- treatment refers to a method performed to obtain a beneficial or desired clinical result.
- a beneficial or desired clinical outcome includes, but is not limited to, relief of symptoms, reduction of the extent of the disease, stabilization (i.e., no longer worsening) of the disease state, delay or slowing of the progression of the disease, amelioration or palliation of the disease status, and relief of symptoms (whether partial or total), whether detectable or undetectable.
- treating can also refer to prolonging survival as compared to expected survival if not receiving treatment.
- the term "subject” refers to mammals, such as humans, monkeys, mice.
- the subject eg, human, monkey, mouse
- has, or is at risk of having, a disease associated with MSLN eg, involving an MSLN-positive tumor.
- an effective amount refers to an amount sufficient to achieve, or at least partially achieve, the desired effect.
- an effective amount for preventing a disease e.g., involving an MSLN-positive tumor
- an effective amount for treating a disease refers to an amount sufficient to cure or at least partially prevent an existing disease
- the amount of the patient's disease and its complications. Determining such an effective amount is well within the capability of those skilled in the art.
- amounts effective for therapeutic use will depend on the severity of the disease to be treated, the general state of the patient's own immune system, the general condition of the patient such as age, weight and sex, the mode of administration of the drug, and other treatments administered concomitantly etc.
- the present invention provides Nanobodies with high binding activity to MSLN, which have cross-reactivity with human, monkey and/or mouse MSLN.
- the nanobody also has the characteristics of small molecular weight and good stability. Compared with traditional common normal antibodies in drug development and diagnostic reagent development, it has good tissue infiltration, flexible administration methods, and a high degree of humanization. , easy recombinant protein transformation and many other advantages.
- the Nanobodies of the invention may be used in a variety of applications including, but not limited to, inhibition of tumor growth and detection of MSLN protein.
- the fully human antibodies of the present invention can be safely administered to human subjects without eliciting immunogenic responses. Therefore, the antibodies of the present invention have great clinical value.
- Figure 1 shows the detection results of the affinity of anti-MSLN nanobodies to CHO-hMSLN cells.
- Figure 2 shows the detection results of the affinity of the humanized anti-MSLN nanobody to CHO-hMSLN cells.
- Figure 3 shows the detection results of the affinity of the humanized anti-MSLN nanobody to CHO-cyMSLN cells.
- Figure 4 shows the detection results of the affinity of the humanized anti-MSLN nanobody to CHO-mMSLN cells.
- Figure 5 shows the detection results of the blocking activity of the humanized anti-MSLN nanobody blocking the binding of human MSLN to its ligand CA125.
- the molecular biology experiment methods and immunoassay methods used in the present invention are basically with reference to J.Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory Press, 1989, and F.M.Ausubel et al., Compiled Molecular Biology Experimental Guide, 3rd Edition, John Wiley & Sons, Inc., 1995 by the method described; restriction endonucleases were used in accordance with the conditions recommended by the product manufacturer.
- restriction endonucleases were used in accordance with the conditions recommended by the product manufacturer.
- the alpaca (Llama) was immunized with human MSLN antigen (purchased from AcroBiosystems, catalog number: MSN-H522a)
- human MSLN antigen purchased from AcroBiosystems, catalog number: MSN-H522a
- the total RNA in the peripheral lymphocytes of the alpaca was extracted and reverse-transcribed to obtain cDNA
- the PCR product of cDNA was combined with the yeast display vector After ligation, it was electrotransformed into Saccharomyces cerevisiae (purchased from ATCC, catalog number: 208289), and an anti-MSLN nanobody library was constructed.
- Human MSLN protein was labeled according to the product instruction of the biotin labeling kit (purchased from Thermo, catalog number: 90407). After the amplified anti-MSLN nanobody yeast library was labeled with biotin-labeled MSLN protein, positively labeled yeast were enriched using magnetic beads.
- the yeast liquid that can be enriched by magnetic beads and flow cytometry and has a higher binding ability to human MSLN antigen was cultured overnight at 30°C and 225rpm in the expansion medium, and the yeast plasmid extraction kit (purchased Yeast plasmids were extracted from Tiangen (product number: DP112).
- the plasmid was electrotransformed into Top10 competent cells (purchased from Tiangen, Cat. No.: CB104-02), coated with ampicillin-resistant plates, and cultured overnight at 37°C. Single clones were picked and sequenced to obtain the VHH (variable region) gene sequence, and the sequence of the CDR region was determined according to the IMGT numbering system.
- the sequence information of the obtained monoclonal nanobody YE-17 is shown in the table below.
- Embodiment 2 Expression vector construction, protein expression and purification of anti-MSLN nanobody
- VHH coding sequence of anti-MSLN antibody YE-17 and the coding sequence of human IgG1 Fc segment (SEQ ID NO: 5) obtained by screening were constructed into a fusion protein expression sequence through homologous recombination, wherein the human IgG1 Fc segment was connected to the C-terminal of VHH.
- the medium-prepared fusion protein expression plasmid was transferred into Expi-CHO cells (purchased from Thermo, catalog number: A2910002), and the transfection method was according to the product manual.
- the supernatant was collected after the cells were cultured for 5 days, and the target protein was purified by sorting with Protein A magnetic beads (purchased from GenScript, catalog number: L00723). Resuspend the magnetic beads with an appropriate volume (1-4 times the volume of magnetic beads) of Binding buffer (PBS+0.1% Tween 20, pH 7.4) and add to the sample to be purified, incubate at room temperature for 1 hour with gentle shaking. The sample was placed on a magnetic stand (purchased from Beaver), the supernatant was discarded, and the magnetic beads were washed 3 times with Binding buffer.
- Protein A magnetic beads purchased from GenScript, catalog number: L00723
- Binding buffer PBS+0.1% Tween 20, pH 7.4
- the antibody amatuximab (CAS No.: 931402-35-6) was set in parallel as a control group, and the light and heavy chain amino acid sequences of the antibody amatuximab are shown in SEQ ID NOs: 18-19. The results are shown in Table 3.
- CHO cells (CHO-hMSLN cells) overexpressing human MSLN (Uniprot ID: Q13421) were prepared by transfecting pCHO1.0 vector of MSLN cDNA (purchased from Invitrogen). Adjust the cell density of the expanded CHO-MSLN cells to 2 ⁇ 10 6 cells/ml, add 100 ⁇ L/well to a 96-well flow plate, and centrifuge for later use.
- the purified anti-MSLN antibody YE-17 prepared in Example 2 was diluted with PBS, starting from 400nM and diluted 3 times, totaling 12 points. Add 100 ⁇ L/well of the above-mentioned diluted sample into the above-mentioned 96-well flow plate with cells, incubate at 4° C.
- the experimental results are shown in Figure 1 and Table 4.
- the experimental results show that the anti-MSLN antibody YE-17 prepared in Example 2 has binding activity to CHO-hMSLN cells, and the binding activity is higher than that of the single-chain control antibody amatuximab from Morphotek.
- the purified humanized antibody was identified at the protein level according to the method described in Example 3, and the results are shown in Table 5.
- Example 6 Detection of binding force between anti-MSLN humanized nanobody and CHO-hMSLN cells and its species cross-recognition characteristics
- the purified humanized antibody was tested for affinity at the CHO-hMSLN cell level according to the method described in Example 4.
- a cell line was constructed according to the method described in Example 4, and the purified humanized antibody was combined with CHO-cyMSLN in the cell level of affinity identification.
- antibody YE-17 and its humanized antibody have cross-binding activity with human and monkey MSLN
- antibody YE-17 and its partially humanized antibody also have certain cross-binding activity with human, monkey and mouse MSLN.
- Example 7 Anti-MSLN humanized Nanobodies block the binding of human MSLN to its ligand CA125
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Abstract
Description
抗体编号 | KD(M) | Kon(1/Ms) | Koff(1/s) |
YE-17 | 1.88E-10 | 5.50E+05 | 1.04E-04 |
amatuximab | 8.13E-10 | 1.53E+06 | 1.24E-03 |
抗体编号 | EC50(nM) |
YE-17 | 0.9647 |
amatuximab | 1.531 |
抗体编号 | KD(M) | Kon(1/Ms) | Koff(1/s) |
YE-17 | 1.40E-09 | 4.21E+05 | 5.90E-04 |
HZ-P-YE-17-01 | 8.07E-10 | 4.02E+05 | 3.25E-04 |
HZ-P-YE-17-02 | 2.20E-09 | 4.03E+05 | 8.88E-04 |
HZ-P-YE-17-03 | 1.91E-08 | 3.36E+05 | 6.40E-03 |
HZ-P-YE-17-04 | 1.93E-08 | 3.29E+05 | 6.36E-03 |
编号 | EC50(nM) |
YE-17 | 0.305 |
HZ-P-YE-17-01 | 0.4775 |
HZ-P-YE-17-02 | 0.5515 |
HZ-P-YE-17-03 | 0.2415 |
HZ-P-YE-17-04 | 0.3399 |
编号 | EC50(nM) |
YE-17 | 0.7161 |
HZ-P-YE-17-01 | 1.24 |
HZ-P-YE-17-02 | 0.6298 |
HZ-P-YE-17-03 | 0.7084 |
HZ-P-YE-17-04 | 1.009 |
编号 | EC50(nM) |
YE-17 | 6.312 |
HZ-P-YE-17-01 | 12.99 |
HZ-P-YE-17-02 | 7.293 |
HZ-P-YE-17-03 | 22.35 |
HZ-P-YE-17-04 | ~249165 |
编号 | EC50(nM) |
YE-17 | 5.958 |
HZ-P-YE-17-01 | 3.342 |
HZ-P-YE-17-02 | 2.627 |
HZ-P-YE-17-03 | 4.753 |
HZ-P-YE-17-04 | 3.234 |
Claims (24)
- 能够特异性结合MSLN的纳米抗体或其抗原结合片段,所述纳米抗体或其抗原结合片段包含:如SEQ ID NOs:4、6-9任一项所示的可变区(VHH)中含有的CDR1或其变体、CDR2或其变体、CDR3或其变体;其中,所述变体与其所源自的序列相比具有一个或几个氨基酸的置换、缺失或添加(例如1个,2个或3个氨基酸的置换、缺失或添加);优选地,所述的置换是保守置换;优选地,所述CDR根据IMGT、Kabat或Chothia编号***定义。
- 权利要求1的纳米抗体或其抗原结合片段,其中,所述纳米抗体或其抗原结合片段包含:序列为SEQ ID NO:1或其变体的CDR1,序列为SEQ ID NO:2或其变体的CDR2,以及,序列为SEQ ID NO:3或其变体的CDR3;其中,所述变体与其所源自的序列相比具有一个或几个氨基酸的置换、缺失或添加(例如1个,2个或3个氨基酸的置换、缺失或添加);优选地,所述的置换是保守置换;优选地,所述纳米抗体或其抗原结合片段包含:序列为SEQ ID NO:1的CDR1,序列为SEQ ID NO:2的CDR2,以及,序列为SEQ ID NO:3的CDR3;优选地,所述CDR由IMGT编号***定义。
- 权利要求1或2的纳米抗体或其抗原结合片段,其包含选自下列的氨基酸序列:(i)如SEQ ID NO:4所示的序列;(ii)与SEQ ID NO:4所示的序列相比具有一个或几个氨基酸的置换、缺失或添加(例如1个,2个,3个,4个或5个氨基酸的置换、缺失或添加)的序列;或(iii)与SEQ ID NO:4所示的序列具有至少80%、至少85%、至少90%、至少91%、至少92%、至少93%、至少94%、至少95%、至少96%、至少97%、至少98%、至少99%、或100%的序列同一性的序列;优选地,所述的置换是保守置换。
- 权利要求1-3任一项的纳米抗体或其抗原结合片段,所述纳米抗体或其抗原结合片段是人源化的;优选地,所述纳米抗体或其抗原结合片段进一步包含人免疫球蛋白的重链框架区(例如,人重链胚系抗体基因所编码的氨基酸序列中所包含的重链框架区),所述重链框架区任选地包含一个或多个(例如,1个、2个、3个、4个、5个、6个、7个、8个、9个或10个)从人源残基至驼源残基的回复突变。
- 权利要求1-4任一项的纳米抗体或其抗原结合片段,所述纳米抗体或其抗原结合片段包含:(i)如SEQ ID NO:10所示或与SEQ ID NO:10相比具有一个或几个氨基酸的置换、缺失或添加(例如1个,2个,3个,4个或5个氨基酸的置换、缺失或添加),或具有至少80%、至少85%、至少90%、至少91%、至少92%、至少93%、至少94%、至少95%、至少96%、至少97%、至少98%、至少99%、或100%的序列同一性的FR1;(ii)如SEQ ID NOs:11-13任一项所示或与SEQ ID NOs:11-13任一项相比具有一个或几个氨基酸的置换、缺失或添加(例如1个,2个,3个,4个或5个氨基酸的置换、缺失或添加),或具有至少80%、至少85%、至少90%、至少91%、至少92%、至少93%、至少94%、至少95%、至少96%、至少97%、至少98%、至少99%、或100%的序列同一性的FR2;(ii)如SEQ ID NOs:14-16任一项所示或与SEQ ID NOs:14-16任一项相比具有一个或几个氨基酸的置换、缺失或添加(例如1个,2个,3个,4个或5个氨基酸的置换、缺失或添加),或具有至少80%、至少85%、至少90%、至少91%、至少92%、至少93%、至少94%、至少95%、至少96%、至少97%、至少98%、至少99%、或100%的序列同一性的FR3;和/或,(iv)如SEQ ID NO:17所示或与SEQ ID NO:17相比具有一个或几个氨基酸的置换、缺失或添加(例如1个,2个,3个,4个或5个氨基酸的置换、缺失或添加),或具有至少80%、至少85%、至少90%、至少91%、至少92%、至少93%、至少94%、至少95%、至少96%、至少97%、至少98%、至少99%、或100%的序列同一性的FR4。
- 权利要求1-5任一项的纳米抗体或其抗原结合片段,所述纳米抗体或其抗原结合片段包含选自下列的氨基酸序列:(i)如SEQ ID NOs:6-9任一项所示的序列;(ii)与SEQ ID NOs:6-9任一项所示的序列相比具有一个或几个氨基酸的置换、缺失或添加(例如1个,2个,3个,4个或5个氨基酸的置换、缺失或添加)的序列;或(iii)与SEQ ID NOs:6-9任一项所示的序列具有至少80%、至少85%、至少90%、至少91%、至少92%、至少93%、至少94%、至少95%、至少96%、至少97%、至少98%、至少99%、或100%的序列同一性的序列;优选地,所述的置换是保守置换。
- 特异性结合MSLN的多肽构建体,其包含权利要求1-6任一项所述的纳米抗体或其抗原结合片段,以及免疫球蛋白Fc结构域;优选地,所述免疫球蛋白Fc结构域任选地通过肽接头连接至所述纳米抗体或其抗原结合片段的N端和/或C端(例如C端);优选地,所述免疫球蛋白Fc结构域是IgG的Fc结构域(例如IgG1的Fc结构域);优选地,所述免疫球蛋白Fc结构域包含SEQ ID NO:5所示的序列,或与其相比具有至少80%、至少85%、至少90%、至少91%、至少92%、至少93%、至少94%、至少95%、至少96%、至少97%、至少98%、至少99%、或100%的序列同一性的序列,或与其相比具有一个或几个氨基酸置换、缺失或添加(例如,1个、2个、3个、4个或5个氨基酸置换、缺失或添加)的序列。
- 分离的核酸分子,其编码权利要求1-6任一项所述的纳米抗体或其抗原结合片段或权利要求7所述的多肽构建体。
- 载体,其包含权利要求8所述的核酸分子;优选地,所述载体为克隆载体或表达载体。
- 宿主细胞,其包含权利要求8所述的核酸分子或权利要求9所述的载体。
- 制备权利要求1-6任一项所述的纳米抗体或其抗原结合片段或权利要求7所述的多肽构建体的方法,其包括,在允许蛋白表达的条件下,培养权利要求10所述的宿主细胞,和从培养的宿主细胞培养物中回收所述纳米抗体或其抗原结合片段或所述多肽构建体。
- 双特异性或多特异性抗体,其包含权利要求1-6任一项所述的纳米抗体或其抗原结合片段或权利要求7所述的多肽构建体;优选地,所述双特异性或多特异性抗体特异性结合MSLN,并且额外地特异性结合一个或多个其他靶标;优选地,所述双特异性或多特异性抗体还包含至少一种具有针对第二靶标的第二结合特异性的第二抗体。
- 缀合物,其包含权利要求1-6任一项所述的纳米抗体或其抗原结合片段或权利要求7所述的多肽构建体,以及与所述纳米抗体或其抗原结合片段或多肽构建体连接的治疗剂;优选地,所述治疗剂选自抗肿瘤药物,例如细胞毒剂、激素类药物、生物反应调节剂、另外的抗体或其抗原结合片段。
- 嵌合抗原受体,其包含抗原结合结构域、间隔结构域、跨膜结构域以及胞内信号传导结构域,其中所述抗原结合结构域包含权利要求1-6任一项所述的纳米抗体或其抗原结合片段;优选地,所述嵌合抗原受体由免疫效应细胞(例如T细胞)所表达。
- 分离的核酸分子,其编码权利要求14所述的嵌合抗原受体。
- 载体,其包含权利要求15所述的分离的核酸分子;优选地,其用于制备嵌合抗原受体T细胞。
- 宿主细胞,其包含权利要求15所述的分离的核酸分子或权利要求16所述的载体;优选地,所述宿主细胞是免疫效应细胞(例如,T细胞或NK细胞);优选地,所述宿主细胞是嵌合抗原受体T细胞(CAR-T)。
- 药物组合物,其包含权利要求1-6任一项的纳米抗体或其抗原结合片段、权利要求7所述的多肽构建体、权利要求8的分离的核酸分子、权利要求9的载体、权利要求10所述的宿主细胞、权利要求12所述的双特异性或多特异性抗体、权利要求13所述的缀合物、权利要求14所述的嵌合抗原受体、权利要求15的分离的核酸分子、权利要求16的载体、或权利要求17所述的宿主细胞;优选地,所述药物组合物还包含药学上可接受的载体和/或赋形剂;优选地,所述药物组合物包含权利要求1-6任一项的纳米抗体或其抗原结合片段、权利要求7所述的多肽构建体、权利要求8的分离的核酸分子、权利要求9的载体或权利要求10所述的宿主细胞;优选地,所述药物组合物包含权利要求12所述的双特异性或多特异性抗体;优选地,所述药物组合物包含权利要求13所述的缀合物;优选地,所述药物组合物包含权利要求14所述的嵌合抗原受体、权利要求15的分离的核酸分子、权利要求16的载体、或权利要求17所述的宿主细胞。
- 权利要求1-6任一项的纳米抗体或其抗原结合片段、权利要求7所述的多肽构建体、权利要求8的分离的核酸分子、权利要求9的载体、权利要求10所述的宿主细胞、权利要求12所述的双特异性或多特异性抗体、权利要求13所述的缀合物、权利要求14所述的嵌合抗原受体、权利要求15的分离的核酸分子、权利要求16的载体、权利要求17所述的宿主细胞、或权利要求18所述的药物组合物用于制备药物的用途,所述药物用于在受试者中预防和/***;优选地,所述肿瘤为MSLN阳性的肿瘤;优选地,所述肿瘤选自实体瘤,例如胃癌、肺癌、卵巢癌、食道癌、胰腺癌、***、间皮瘤或乳腺癌;优选地,所述受试者为哺乳动物,例如人;优选地,所述纳米抗体或其抗原结合片段、多肽构建体、分离的核酸分子、载体、宿主细胞、双特异性或多特异性抗体、缀合物、嵌合抗原受体、或药物组合物单独使用,或与另外的药学活性剂(例如抗肿瘤剂)联合使用。
- 用于在受试者中预防和/或***的方法,其包括:给有此需要的受试者施用有效量的权利要求1-6任一项的纳米抗体或其抗原结合片段、权利要求7所述的多肽构建体、权利要求8的分离的核酸分子、权利要求9的载体、权利要求10所述的宿主细胞、权利要求12所述的双特异性或多特异性抗体、权利要求13所述的缀合物、权利要求14所述的嵌合抗原受体、权利要求15的分离的核酸分子、权利要求16的载体、权利要求17所述的宿主细胞、或权利要求18所述的药物组合物;优选地,所述肿瘤为MSLN阳性的肿瘤;优选地,所述肿瘤选自实体瘤,例如胃癌、肺癌、卵巢癌、食道癌、胰腺癌、***、间皮瘤或乳腺癌;优选地,所述受试者为哺乳动物,例如人。
- 缀合物,其包含权利要求1-6任一项所述的纳米抗体或其抗原结合片段或权利要求7所述的多肽构建体,以及与所述纳米抗体或其抗原结合片段或多肽构建体连接的可检测的标记,例如酶(例如辣根过氧化物酶或碱性磷酸酶)、化学发光试剂(例如吖啶酯类化合物、鲁米诺及其衍生物、或钌衍生物)、荧光染料(例如荧光素或荧光蛋白)、放射性核素或生物素。
- 试剂盒,其包括权利要求1-6任一项所述的纳米抗体或其抗原结合片段或权利要求7所述的多肽构建体或权利要求21所述的缀合物;优选地,所述试剂盒包含权利要求21所述的缀合物;优选地,所述试剂盒包含权利要求1-6任一项所述的纳米抗体或其抗原结合片段或权利要求7所述的多肽构建体,以及特异性识别所述纳米抗体或其抗原结合片段或多肽构建体的第二抗体;任选地,所述第二抗体还包括可检测的标记,例如酶(例如辣根过氧化物酶或碱性磷酸酶)、化学发光试剂(例如吖啶酯类化合物、鲁米诺及其衍生物、或钌衍生物)、荧光染料(例如荧光素或荧光蛋白)、放射性核素或生物素。
- 用于检测MSLN在样品中的存在或其水平的方法,其包括使用权利要求1-6任一项所述的纳米抗体或其抗原结合片段或权利要求7所述的多肽构建体或权利要求21所述的缀合物;优选地,所述方法是免疫学检测,例如免疫印迹法、酶免疫测定法(例如ELISA)、化学发光免疫分析法、荧光免疫分析法或放射免疫测定法;优选地,所述方法包括使用权利要求21所述的缀合物;优选地,所述方法包括使用权利要求1-6任一项所述的纳米抗体或其抗原结合片段或权利要求7所述的多肽构建体,并且所述方法还包括使用携带可检测的标记(例如酶(例如辣根过氧化物酶或碱性磷酸酶)、化学发光试剂(例如吖啶酯类化合物、鲁米诺及其衍生物、或钌衍生物)、荧光染料(例如荧光素或荧光蛋白)、放射性核素或生物素)的第二抗体来检测所述纳米抗体或其抗原结合片段或多肽构建体。
- 权利要求1-6任一项所述的纳米抗体或其抗原结合片段或权利要求7所述的多肽构建体或权利要求21所述的缀合物在制备用于检测MSLN在样品中的存在或其水平或者用于检测肿瘤是否能够通过靶向MSLN的抗肿瘤疗法来治疗的检测试剂中的用途;优选地,所述检测试剂通过权利要求23所述的方法来检测MSLN在样品中的存在或其水平以及任选地检测肿瘤是否能够通过靶向MSLN的抗肿瘤疗法来治疗;优选地,所述样品为来自受试者(例如哺乳动物,例如人)的细胞样品(例如包含肿瘤细胞的样品)或体液样品(例如血液)。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2022373543A AU2022373543A1 (en) | 2021-10-18 | 2022-10-13 | Anti-mesothelin nanobodies and use thereof |
CA3235697A CA3235697A1 (en) | 2021-10-18 | 2022-10-13 | Anti-mesothelin nanobodies and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111208871.9A CN115991782A (zh) | 2021-10-18 | 2021-10-18 | 抗间皮素纳米抗体及其用途 |
CN202111208871.9 | 2021-10-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023066133A1 true WO2023066133A1 (zh) | 2023-04-27 |
Family
ID=85989010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2022/125135 WO2023066133A1 (zh) | 2021-10-18 | 2022-10-13 | 抗间皮素纳米抗体及其用途 |
Country Status (4)
Country | Link |
---|---|
CN (1) | CN115991782A (zh) |
AU (1) | AU2022373543A1 (zh) |
CA (1) | CA3235697A1 (zh) |
WO (1) | WO2023066133A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116466097B (zh) * | 2023-06-14 | 2023-08-29 | 天津市协和医药科技集团有限公司 | 一种人胰岛素检测试剂盒 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103819559A (zh) * | 2013-12-10 | 2014-05-28 | 中国科学院武汉病毒研究所 | 一种抗间皮素的纳米抗体及其编码基因和该纳米抗体的用途 |
CN106459989A (zh) * | 2013-12-19 | 2017-02-22 | 诺华股份有限公司 | 人间皮素嵌合抗原受体及其用途 |
CN108129566A (zh) * | 2017-12-31 | 2018-06-08 | 中国科学院武汉病毒研究所 | 靶向间皮素的高亲和力c-型单域抗体及其制备方法与应用 |
CN109467605A (zh) * | 2018-11-07 | 2019-03-15 | 南京卡提医学科技有限公司 | 嵌合抗原受体DAP12-T2A-CD8α-MSLN scFv-NKp44及其用途 |
CN110698562A (zh) * | 2019-10-31 | 2020-01-17 | 浙江蓝盾药业有限公司 | 抗人msln单克隆抗体 |
CA3141085A1 (en) * | 2019-06-19 | 2020-12-24 | Brenda Stevens | Anti-mesothelin antibodies and immunoconjugates thereof |
CN112703205A (zh) * | 2018-07-12 | 2021-04-23 | F星贝塔有限公司 | 抗间皮素抗体 |
-
2021
- 2021-10-18 CN CN202111208871.9A patent/CN115991782A/zh active Pending
-
2022
- 2022-10-13 AU AU2022373543A patent/AU2022373543A1/en active Pending
- 2022-10-13 CA CA3235697A patent/CA3235697A1/en active Pending
- 2022-10-13 WO PCT/CN2022/125135 patent/WO2023066133A1/zh active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103819559A (zh) * | 2013-12-10 | 2014-05-28 | 中国科学院武汉病毒研究所 | 一种抗间皮素的纳米抗体及其编码基因和该纳米抗体的用途 |
CN106459989A (zh) * | 2013-12-19 | 2017-02-22 | 诺华股份有限公司 | 人间皮素嵌合抗原受体及其用途 |
CN108129566A (zh) * | 2017-12-31 | 2018-06-08 | 中国科学院武汉病毒研究所 | 靶向间皮素的高亲和力c-型单域抗体及其制备方法与应用 |
CN112703205A (zh) * | 2018-07-12 | 2021-04-23 | F星贝塔有限公司 | 抗间皮素抗体 |
CN109467605A (zh) * | 2018-11-07 | 2019-03-15 | 南京卡提医学科技有限公司 | 嵌合抗原受体DAP12-T2A-CD8α-MSLN scFv-NKp44及其用途 |
CA3141085A1 (en) * | 2019-06-19 | 2020-12-24 | Brenda Stevens | Anti-mesothelin antibodies and immunoconjugates thereof |
CN110698562A (zh) * | 2019-10-31 | 2020-01-17 | 浙江蓝盾药业有限公司 | 抗人msln单克隆抗体 |
Also Published As
Publication number | Publication date |
---|---|
CN115991782A (zh) | 2023-04-21 |
AU2022373543A1 (en) | 2024-05-16 |
CA3235697A1 (en) | 2023-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113166246A (zh) | 一种抗体及其用途 | |
WO2019091436A1 (zh) | 4-1bb抗体及其制备方法和应用 | |
CN110799546B (zh) | 重组双特异性抗体 | |
WO2021170082A1 (zh) | 抗cd47/抗pd-l1抗体及其应用 | |
WO2022068810A1 (zh) | 抗Claudin18.2和CD3的双特异性抗体以及其用途 | |
WO2022228183A1 (zh) | 抗siglec15抗体及其制备方法和用途 | |
WO2023066133A1 (zh) | 抗间皮素纳米抗体及其用途 | |
CN113583116A (zh) | 针对SARS-CoV-1或SARS-CoV-2的抗体及其用途 | |
CN113583115A (zh) | 针对SARS-CoV-2的抗体及其用途 | |
CN117362422A (zh) | 针对SARS-CoV-2的抗体及其用途 | |
WO2023217216A1 (zh) | 一种三特异性抗体的设计、制备及用途 | |
WO2019192493A1 (zh) | 抗人lag-3单克隆抗体及其应用 | |
KR20220044748A (ko) | 4가 대칭 이중 특이적 항체 | |
WO2022267936A1 (zh) | 特异性结合糖基化ceacam5的抗体 | |
WO2021244392A1 (zh) | 一种抗pd1×pdl1的双特异性抗体 | |
WO2021244371A1 (zh) | 一种抗pd-l1/vegf融合蛋白 | |
WO2022042494A1 (zh) | Cd22抗体及其应用 | |
WO2024007671A1 (zh) | 特异性结合cd24的抗体及其用途 | |
WO2024017281A1 (zh) | 多特异性抗体及其用途 | |
WO2022268168A1 (zh) | 靶向lag-3和pd-l1的新型双特异抗体及其应用 | |
WO2022117050A1 (zh) | 一种新型肿瘤衔接器治疗药物的开发和应用 | |
WO2023016450A1 (zh) | 抗tigit抗体及其用途 | |
WO2024061224A1 (zh) | 抗her2抗体及其用途 | |
WO2023186121A1 (en) | Anti-cd39 nanobody and uses thereof | |
CN114426580B (zh) | 抗csf-1r抗体及其产品、方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22882743 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3235697 Country of ref document: CA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112024007609 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: AU2022373543 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2022373543 Country of ref document: AU Date of ref document: 20221013 Kind code of ref document: A |